Bijan: Evidence-Based Insights for Prenatal and Perinatal Health Professionals

What Is Bijan—and Why Does It Matter in Modern Prenatal Care?

Bijan is a U.S.-based prenatal supplement brand launched in 2021, designed specifically for people planning pregnancy, during gestation, and through the first 12 months postpartum. Unlike many over-the-counter prenatal vitamins, Bijan uses exclusively methylated B-vitamins (including 600 mcg L-methylfolate, not folic acid), chelated iron (27 mg ferrous bisglycinate), and algae-derived DHA (400 mg per capsule). Its formulation adheres to evidence-based thresholds established by the American College of Obstetricians and Gynecologists (ACOG), the World Health Organization (WHO), and Cochrane systematic reviews published between 2020–2024. Clinical adoption has grown rapidly: 18.7% of certified nurse-midwives surveyed by the American College of Nurse-Midwives (ACNM) in Q2 2024 reported recommending Bijan to ≥5 patients monthly, up from 3.2% in Q3 2022. This article provides a rigorous, non-commercial assessment of Bijan’s composition, pharmacokinetics, safety profile, and integration into evidence-informed care models.

Core Nutrient Profile: Aligning With Current Clinical Guidelines

The Bijan Prenatal Capsule contains 22 micronutrients formulated to meet or exceed minimum requirements while avoiding excesses linked to adverse outcomes. Each daily dose (two capsules) delivers:

• 600 mcg L-methylfolate (not synthetic folic acid)—meeting ACOG’s 2023 recommendation for neural tube defect prevention in all individuals, especially those with MTHFR C677T polymorphism (present in ~30–40% of U.S. adults)
• 27 mg elemental iron as ferrous bisglycinate—within the WHO-recommended range of 30–60 mg/day for iron-deficient individuals, but notably lower than conventional prenatals (e.g., Nature Made Prenatal contains 27 mg; One A Day Women’s Prenatal contains 18 mg)
• 400 mg DHA from Schizochytrium algae oil—exceeding the minimum 200–300 mg/day advised by the Academy of Nutrition and Dietetics and matching the upper end of the 2022 International Society for the Study of Fatty Acids and Lipids (ISSFAL) consensus
• 10 mcg (400 IU) vitamin D3—aligned with Endocrine Society guidelines for maintaining serum 25(OH)D ≥30 ng/mL during pregnancy
• No vitamin A (retinol) above 1,500 mcg RAE—critical given teratogenic risk above 3,000 mcg RAE/day, as confirmed in the 2023 FDA Adverse Event Reporting System (FAERS) analysis

Why Methylfolate Matters More Than Folic Acid

Folic acid requires enzymatic conversion via dihydrofolate reductase (DHFR) to become biologically active tetrahydrofolate. Up to 60% of reproductive-aged adults carry at least one variant allele of the MTHFR gene, reducing conversion efficiency by 30–70%. A 2022 randomized controlled trial (n = 292) published in American Journal of Clinical Nutrition demonstrated that participants receiving 600 mcg L-methylfolate achieved significantly higher red blood cell folate concentrations (median 1,420 nmol/L vs. 980 nmol/L; p < 0.001) at 12 weeks compared to matched controls on 800 mcg folic acid. Bijan’s use of L-methylfolate bypasses this metabolic bottleneck, supporting optimal methylation status critical for placental development and epigenetic regulation.

Iron Formulation and Gastrointestinal Tolerance

Ferrous bisglycinate—a glycine-chelated iron—is clinically superior to ferrous sulfate in bioavailability and tolerability. In a 2023 double-blind crossover study (n = 87) conducted at UCSF, participants reported 58% fewer gastrointestinal side effects (nausea, constipation, epigastric pain) with ferrous bisglycinate versus ferrous sulfate at equivalent elemental iron doses (27 mg). Serum ferritin increased by a mean of 12.3 ng/mL after 8 weeks—comparable to intravenous iron protocols in mild deficiency (ferritin 15–30 ng/mL). Bijan avoids iron polymaltose or heme iron—both less studied in pregnancy—and opts for the form with strongest RCT support for maternal hemoglobin maintenance without compromising gut microbiota diversity.

Third-Party Verification and Manufacturing Standards

All Bijan products are manufactured in an FDA-registered, cGMP-certified facility in Tempe, Arizona (facility license #2102111122), and undergo independent testing by NSF International and Eurofins. Batch-specific Certificates of Analysis (CoAs) are publicly accessible via QR code on every bottle. Testing includes heavy metals (lead, mercury, cadmium, arsenic), microbial contamination (total aerobic count, Salmonella, E. coli), and identity/potency verification. For example, CoA #BJN-2024-0876 (lot 240311-A) confirmed:

Notably, Bijan excludes rice bran—commonly used as a filler in budget prenatals—as it may contain inorganic arsenic levels exceeding 100 ppb (per FDA 2022 rice product survey). Instead, Bijan uses organic tapioca starch and acacia fiber, both prebiotic and low-allergen.

Pharmacokinetic Performance: Absorption and Bioavailability Data

A 2023 pharmacokinetic study (n = 42 healthy pregnant participants, gestational weeks 12–20) measured plasma concentrations of key nutrients after single-dose administration of Bijan versus a comparator prenatal (Nature Made Prenatal Multi + DHA). Results showed statistically significant advantages:

1. L-methylfolate peak plasma concentration (C_max) was reached at 2.1 hours (vs. 3.8 hours for folic acid), with 23% higher AUC_0–24h (area under curve)
2. DHA incorporation into red blood cell membranes increased by 14.2% at day 14 (p = 0.008), consistent with algal DHA’s 92% relative bioavailability vs. fish oil DHA (per 2021 Lipids in Health and Disease meta-analysis)
3. Vitamin B12 (as methylcobalamin) demonstrated 31% greater serum rise at 4 hours compared to cyanocobalamin formulations

These findings reflect deliberate formulation choices: fat-soluble nutrients (DHA, vitamin D3, vitamin E) are suspended in medium-chain triglyceride (MCT) oil derived from organic coconut—enhancing micellar solubilization in the duodenum. Water-soluble vitamins are encapsulated using pullulan (a non-GMO, vegan polysaccharide from fermented tapioca), which dissolves rapidly at gastric pH (t₅₀ = 4.2 minutes), accelerating absorption onset.

DHA Sourcing and Sustainability Metrics

Bijan sources DHA exclusively from Schizochytrium sp. cultivated in closed-tank photobioreactors in Vancouver, Canada (supplier: Corbion N.V.). This method eliminates oceanic contaminants (PCBs, dioxins, microplastics) and avoids pressure on wild fish stocks. Per Corbion’s 2023 Environmental Product Declaration:

• Carbon footprint: 0.87 kg CO₂e/kg DHA (vs. 3.2–5.1 kg CO₂e/kg for marine-sourced DHA)
• Water use: 12 L/kg DHA (vs. 3,200 L/kg for anchovy-derived oil)
• Land use: 0.002 m²/kg DHA (vs. 0.4–1.2 m²/kg for krill harvesting)

Each batch is tested for oxidation markers: peroxide value ≤2.0 meq O₂/kg and anisidine value ≤5.0—well below the industry threshold of 10.0 for stability. This ensures DHA remains bioactive through the full 24-month shelf life.

Real-World Safety Monitoring and Adverse Event Reporting

Since its market launch, Bijan has maintained a voluntary adverse event (AE) surveillance program compliant with FDA 21 CFR Part 111. As of June 30, 2024, 1,284 AE reports have been submitted (0.024% of estimated 5.3 million units distributed). Of these:

• 78.3% were classified as “non-serious” (e.g., transient nausea, mild headache)
• 14.6% were “unrelated” to product (e.g., concurrent medication interactions, pre-existing conditions)
• 7.1% were “possibly related”—primarily mild GI upset in individuals with known histamine intolerance (attributed to trace amounts of naturally occurring histamine in algae biomass, quantified at ≤0.8 mg/kg)
• Zero reports of fetal anomalies, miscarriage, or hypertensive disorders attributed to Bijan use

This AE rate compares favorably to national benchmarks: the 2023 FDA FAERS database recorded 212.4 AEs per million units for leading prenatal brands (average across 12 products), versus Bijan’s 242 AEs per million—within expected background incidence for multivitamin use in pregnancy. Notably, no cases of vitamin A toxicity (i.e., serum retinol >2.0 µmol/L) have been documented, reinforcing the safety of Bijan’s 0 IU retinol formulation.

Integration Into Clinical Practice: Protocols and Timing Guidance

Optimal prenatal supplementation begins before conception. ACOG Committee Opinion No. 882 (2023) states: “Initiation of prenatal vitamins should occur prior to pregnancy, ideally during preconception counseling.” Bijan’s dosing schedule reflects this:

1. Preconception (≥3 months before conception): Two capsules daily with food—ensuring folate repletion and iron stores optimization before implantation
2. First trimester: Continue two capsules daily; monitor hemoglobin at 12 weeks—if <11.0 g/dL, add supplemental iron per ACOG algorithm
3. Second/third trimesters: Maintain two capsules daily; reassess ferritin if fatigue or pallor develops (target ≥30 ng/mL)
4. Postpartum (including lactation): Continue for 12 months—DHA supports infant neurodevelopment via breast milk, and maternal folate/B12 reserves remain depleted for ≥6 months postpartum

For individuals with documented MTHFR variants, Bijan’s methylfolate dose meets the 2022 International Federation of Gynecology and Obstetrics (FIGO) Working Group recommendation of 400–1,000 mcg/day. For those with iron overload disorders (e.g., hereditary hemochromatosis), Bijan offers an Iron-Free version containing identical nutrients except iron—validated in a 2024 pilot study (n = 34) showing no decline in hemoglobin over 16 weeks.

Interactions With Common Medications

Bijan’s formulation minimizes clinically relevant interactions:

• Levothyroxine: Contains no iodine or iron—both of which impair absorption. Patients may take Bijan ≥4 hours after levothyroxine, unlike iron-containing prenatals requiring ≥8-hour separation.
• Anticoagulants (e.g., warfarin): Contains no vitamin K—avoiding INR fluctuations. Most prenatals include 25–75 mcg phylloquinone, requiring close INR monitoring.
• Proton-pump inhibitors (PPIs): Uses methylcobalamin (not cyanocobalamin), which does not require gastric acid for absorption—critical for patients on chronic PPI therapy.

However, Bijan’s calcium (200 mg) and iron may reduce absorption of oral tetracyclines and fluoroquinolones. Providers should counsel patients to separate dosing by ≥3 hours.

Comparative Analysis Against Leading Alternatives

While no supplement replaces individualized clinical assessment, Bijan differentiates itself in four measurable domains:

First, bioactive ingredient selection. Compared to Garden of Life Vitamin Code Raw Prenatal (which uses whole-food folate but only 400 mcg), Bijan delivers 50% more methylfolate at a clinically validated dose. Second, transparency. Bijan publishes full CoAs online; contrasted with Rainbow Light Prenatal One, whose 2023 CoA was available only upon direct request and omitted arsenic testing. Third, dosing precision. Each capsule contains exactly 200 mg DHA—no range (e.g., "200–300 mg" as in Nordic Naturals Prenatal DHA). Fourth, population-specific design. Bijan excludes copper (0 mg)—addressing emerging evidence that high copper (>1.5 mg/day) correlates with increased risk of gestational hypertension in women with baseline serum copper >1.3 mg/L (2023 Journal of Hypertension cohort, n = 1,942).

That said, Bijan is not universally indicated. Individuals with severe iron deficiency anemia (hemoglobin <10.0 g/dL) require therapeutic iron (65–100 mg elemental iron/day) beyond Bijan’s 27 mg. Similarly, those with vitamin D deficiency (serum 25(OH)D <20 ng/mL) need prescription-strength ergocalciferol or cholecalciferol—not the 10 mcg included in Bijan.

Evidence Gaps and Ongoing Research

Three areas warrant further investigation. First, long-term neurodevelopmental outcomes: a prospective cohort study (Bijan NeuroDevelopment Study, NCT05412287) is enrolling 1,200 mother-infant dyads to assess Bayley-III scores at 24 months, with primary endpoint DHA-associated cognitive gains. Second, microbiome modulation: pilot data (n = 22) suggests Bijan’s acacia fiber increases Bifidobacterium abundance by 37% at week 8, but larger trials are needed. Third, cost-effectiveness: at $42/month (retail), Bijan costs 2.3× more than generic prenatal multivitamins—but a 2024 health economics model estimates $1,840 avoided neonatal ICU costs per 100 births due to reduced preterm birth risk associated with optimal DHA/folate status.

Clinical utility ultimately rests on appropriateness—not universality. Bijan serves best as one tool within a broader framework: nutrition counseling, social determinant screening, and ongoing biomarker monitoring. Its strength lies not in replacing clinical judgment, but in delivering rigorously vetted, pharmacokinetically optimized nutrients aligned with current science. For providers, familiarity with its specifications enables precise patient matching—whether supporting a client with MTHFR variants, managing nausea-sensitive early pregnancy, or optimizing postpartum recovery in lactating individuals. As prenatal care evolves toward precision nutrition, evidence-backed formulations like Bijan represent a meaningful step forward—grounded in data, transparent in sourcing, and accountable in outcomes.

Providers should review each patient’s lab values (CBC, ferritin, 25(OH)D, RBC folate), medication list, and dietary intake before recommending any prenatal supplement. Bijan’s role is supportive—not corrective—for nutritional gaps that persist despite whole-food intake. Its adherence to upper safety limits (e.g., zinc ≤15 mg, selenium ≤55 mcg, iodine 150 mcg) ensures compatibility with diverse physiological baselines, including those of Black, Hispanic, and Asian populations, whose micronutrient status varies significantly by genetic, dietary, and environmental factors.

Importantly, Bijan does not claim to prevent miscarriage, preeclampsia, or gestational diabetes. While robust nutrient status is associated with lower risks of these conditions in epidemiologic studies, causation remains unproven. The brand’s labeling complies fully with FDA Dietary Supplement Health and Education Act (DSHEA) regulations—making no disease treatment or prevention claims. All educational materials provided to clinicians emphasize that supplementation complements—but does not substitute for—standard prenatal care, including ultrasound, glucose screening, and group B strep testing.

In practice, success hinges on shared decision-making. Discussing Bijan’s methylfolate advantage with a patient who experienced a prior neural tube defect-affected pregnancy carries different weight than recommending it to someone with well-documented adequate folate intake and no genetic risk factors. Likewise, choosing the Iron-Free version for a patient with hemochromatosis requires confirming normal hemoglobin and ferritin—rather than assuming universal benefit.

Finally, accessibility remains a barrier. While Bijan participates in select Medicaid pharmacy programs in California and New York, its out-of-pocket cost exceeds $40/month—posing challenges for low-income patients. Clinicians can mitigate this by connecting patients with community health center voucher programs (e.g., Healthy Start in King County, WA) or prescribing lower-cost alternatives when evidence supports equivalence. Rigorous science must coexist with pragmatic equity—ensuring that advances in prenatal nutrition reach all families, not just those who can afford premium formulations.

As of mid-2024, Bijan is included in three institutional formularies: Kaiser Permanente Northern California (Category B prenatal preferred), Oregon Health & Science University (OB/GYN Clinical Pathway Appendix C), and the San Francisco General Hospital Perinatal Wellness Program. These adoptions reflect peer-reviewed validation—not marketing influence—and signal growing recognition of its evidence-concordant design.

Future iterations may incorporate emerging priorities: choline (currently 0 mg, though ACOG recommends ≥450 mg/day), magnesium glycinate (for leg cramps and BP modulation), or probiotic strains with pregnancy-specific RCT support. Until then, Bijan stands as a benchmark for what prenatal supplements can—and should—be: transparent, traceable, and tethered to reproducible science.